Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medacta GroupXSWX:MOVE +1.30%91 Median PS Value is CHF0.00 as of Jul. 17, 2026. GuruFocus rates XSWX:MOVE with a GF Score™ of 91/100 and a GF Value™ of CHF168.33 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 336 Medical Devices & Instruments companies, Medacta Group ranks worse than 297618.75% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Medacta Group's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was CHF32.034. Medacta Group's 10-Year median PS Ratio is 0. Therefore, the Median PS Value for today is CHF0.00.
As of today (2026-07-17), Medacta Group's share price is CHF139.80. Medacta Group's Median PS Value is CHF0.00. Therefore, Medacta Group's Price to Median PS Value for today is 0.00.
The historical rank and industry rank for Medacta Group's Median PS Value or its related term are showing as below:
XSWX:MOVE's Price-to-Median-PS-Value is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 0.71 * Ranked among companies with meaningful Price-to-Median-PS-Value only.
Medacta Group (XSWX:MOVE) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Medacta Group's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
139.80
/
0.00
=
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medacta Group Median PS Value Related Terms
Medacta Group Median PS Value Historical Data
* Premium members only.
The historical data trend for Medacta Group's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:MOVE vs ABT, SYK, MDT: Median PS Value Comparison
For the Medical Devices subindustry, Medacta Group's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medacta Group Price-to-Median-PS-Value vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Medacta Group's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Medacta Group's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 0.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Medacta Group's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was CHF32.034.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medacta Group (XSWX:MOVE) has a Median PS Value of CHF0.00 as of Jul. 17, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Medacta Group and its competitors. According to the industry distribution chart, Medacta Group ranks #999999 out of 336 companies in the Medical Devices & Instruments industry.
Is Medacta Group's Median PS Value too high?
Medacta Group's current Median PS Value is CHF0.00. Based on the distribution chart, Medacta Group ranks #999999 out of 336 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Medacta Group has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medacta Group's Median PS Value compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Medacta Group ranks #999999 out of 336 companies for Median PS Value. This places Medacta Group in the lower half of its industry. The industry median Median PS Value is 0.71. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Medical Devices & Instruments company?
The median Median PS Value among Medical Devices & Instruments companies is 0.71, based on 336 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Medacta Group and its competitors. For the Medical Devices & Instruments industry, the median Median PS Value is 0.71 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medacta Group's current Median PS Value is CHF0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medacta Group stock overvalued right now?
Based on GuruFocus' analysis, Medacta Group (XSWX:MOVE) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF168.33, compared to a current price of CHF139.80 — trading 16.9% below its estimated fair value. The current Median PS Value is CHF0.00. Medacta Group's overall GF Score™ is 91/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Medacta Group (XSWX:MOVE), the current Median PS Value is CHF0.00 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medacta Group (XSWX:MOVE) Overvalued in 2026?
Based on GuruFocus' analysis, Medacta Group stock appears to be undervalued.
The current stock price of CHF139.80 is trading 16.9% below its estimated GF Value™ of CHF168.33.
GuruFocus considers Medacta Group to be Modestly Undervalued.
Key valuation signals for XSWX:MOVE:
Median PS Value: CHF0.00
GF Value™: CHF168.33 vs. price of CHF139.80 (16.9% below fair value)
No single metric tells the full story. See the XSWX:MOVE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medacta Group SA is involved in developing, manufacturing, and distributing orthopedic and neurosurgical medical devices. It specializes in the design, production, and distribution of personalized and sustainable solutions for joint replacement, sports medicine, and spine surgery. Medacta's product portfolio includes hip, knee, shoulder, and spine replacement solutions, along with a comprehensive range of sports medicine. Its products and surgical techniques are supported by an extensive program of surgeon education and engagement initiatives, enabling its offerings to be effective for the patient and surgeon. Geographically, the company derives maximum revenue from EMEA (which includes Europe, Middle East and Africa), followed by North America, Asia-Pacific, and the Latin America markets.
91GF Score
Get the complete analysis for XSWX:MOVE
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:MOVE has been successfully added to your 
